PMOS (Polyendocrine Metabolic Ovarian Syndrome): The Complete Guide for South African Women

Whether you have a diagnosis, suspect you have PMOS, or are trying to understand why your hormones, weight, skin, and mood have been consistently dysregulated, this guide gives you the full clinical picture and a clear, root-cause path forward.

What Is PMOS and Why Was the Name Changed?

Polyendocrine Metabolic Ovarian Syndrome, or PMOS, is the updated name for the condition previously called Polycystic Ovarian Syndrome (PCOS). The rename was formalised in a May 2025 Lancet consensus paper reflecting decades of accumulating evidence that the condition is far broader than the original name suggested.

PMOS is now understood as a condition of systemic hormonal and metabolic dysregulation. The ovarian effects, including irregular cycles, anovulation, and follicular cysts, are produced by upstream drivers: insulin resistance, elevated androgens, disrupted LH/FSH signalling, adrenal dysfunction, and chronic inflammation. Treating only the ovarian symptoms, as many conventional approaches do, without addressing these root causes is why outcomes are so frequently incomplete.

How Common Is PMOS in South African Women?

PMOS affects approximately 8 to 13 percent of women of reproductive age globally, making it the most common endocrine condition in women. South African data, while limited, suggests prevalence at the higher end of the global range, with several factors contributing to elevated risk in the local population.

Insulin resistance, the central metabolic driver of PMOS, is particularly prevalent in South Africa due to the interaction of dietary patterns high in refined carbohydrates, high chronic stress loads, and genetic predisposition among several South African population groups. Urban Black South African women appear to carry a specific pattern of PMOS that presents with strong metabolic features and insulin resistance but sometimes without the hyperandrogenism and hirsutism more typical in other ethnic groups, which means symptoms are different enough that the condition is frequently missed entirely.

The Full Spectrum of PMOS Symptoms

PMOS produces symptoms across multiple body systems simultaneously, which is why it is so frequently misdiagnosed or incompletely treated. The symptom picture varies between individuals depending on which of the four PMOS types applies, which is covered in the next section.

What Causes PMOS: The Root-Cause Picture

PMOS does not have a single cause. It is the result of several intersecting drivers that create a self-reinforcing hormonal and metabolic cycle. Understanding each driver is essential for understanding why a single-focus treatment so rarely resolves the full condition.

Insulin Resistance: The Central Driver

Insulin resistance is present in up to 80 percent of PMOS cases and is the most clinically important driver of the condition’s metabolic features. When cells become resistant to insulin, the pancreas compensates by producing more. Chronically elevated insulin directly stimulates the theca cells of the ovaries to produce excess testosterone. It also suppresses the liver’s production of sex hormone binding globulin (SHBG), which means more testosterone is biologically free and active. The result is a hyperandrogenic state that drives acne, hirsutism, and hair loss, and simultaneously disrupts the LH surge needed for ovulation, producing irregular cycles and anovulation. Insulin resistance is the thread that connects the metabolic and reproductive features of PMOS in a single mechanistic loop.

HPA Axis Dysregulation and Adrenal Androgens

The adrenal glands produce a significant proportion of androgens in women, including DHEA-S and androstenedione. In women under chronic stress, adrenal androgen production is amplified, contributing to the hyperandrogenic picture independently of ovarian androgen excess. This is why stress management is not peripheral to PMOS treatment. It is a direct androgen-lowering intervention. South African women carrying significant chronic stress loads have a specific vulnerability to adrenal-driven PMOS that is frequently missed when assessment focuses only on ovarian androgens.

Chronic Inflammation

Low-grade systemic inflammation is now recognised as both a feature and a driver of PMOS. Inflammatory signalling directly stimulates ovarian androgen production and impairs insulin receptor function, worsening insulin resistance. Dietary triggers of inflammation, particularly refined carbohydrates, seed oils, and food sensitivities, interact with gut dysbiosis and environmental toxin exposure to maintain the inflammatory state that keeps PMOS active even when dietary changes appear reasonable on the surface.

Gut Dysbiosis

Women with PMOS consistently show altered gut microbiome composition compared to controls, with reduced microbial diversity and changes in the species responsible for short-chain fatty acid production and androgen metabolism. The gut microbiome directly influences insulin sensitivity, systemic inflammation, oestrogen recycling through the oestrobolome, and even the hypothalamic signalling that governs LH and FSH release. Gut health is not a secondary concern in PMOS; it is a mechanistic target.

Genetic Predisposition

PMOS has a significant heritable component, running in families through both the maternal and paternal lines. If your mother, sister, or maternal aunt has PMOS, your risk is significantly elevated. Genetic predisposition does not mean the condition is inevitable. It means the threshold for environmental triggers to tip the system into PMOS is lower, making early identification of risk factors and preventive lifestyle measures particularly valuable.

The Four Clinical Types of PMOS

Not all PMOS presentations are identical. Recognising the four clinical subtypes matters because each has a different primary driver and responds to a different treatment emphasis. Treating a woman with adrenal PMOS as if she had classic insulin-driven PMOS produces incomplete results.

How PMOS Is Diagnosed in South Africa

The current diagnostic standard uses the Rotterdam Criteria, which requires two of the following three features: irregular or absent ovulation, clinical or biochemical evidence of excess androgens, and polycystic ovarian morphology on ultrasound. With PMOS, the expectation is that updated criteria will place greater emphasis on metabolic markers, particularly fasting insulin and insulin resistance assessment, which are currently not part of the formal diagnostic criteria despite being present in the majority of cases.

Blood Markers to Request

A comprehensive PMOS diagnostic panel should include free and total testosterone, DHEA-S, SHBG, LH and FSH with their ratio, anti-Mullerian hormone (AMH), fasting insulin, fasting glucose and HbA1c, a full thyroid panel with free T3, anti-TPO antibodies, oestradiol, progesterone timed to the luteal phase, full lipid panel, and CRP as an inflammatory marker. Ferritin, vitamin D, zinc, and magnesium round out the nutritional picture. This is a considerably more comprehensive panel than the basic hormone and glucose screen typically ordered in primary care.

Why Ultrasound Alone Is Insufficient

A pelvic ultrasound showing polycystic ovarian morphology is a supportive finding, not a standalone diagnosis. Many women without PMOS have multiple follicles on ultrasound, particularly in the years after puberty or while using hormonal contraception. Conversely, women with clear PMOS features including insulin resistance, irregular cycles, and androgen excess may not show classic polycystic morphology on imaging. Diagnosis should be based on the full clinical and biochemical picture rather than imaging alone.

Getting Diagnosed in South Africa

The diagnostic journey for PMOS in South Africa typically begins with a GP or gynaecologist. However, because the comprehensive metabolic panel described above is rarely ordered in full through standard primary care, many women receive either a partial diagnosis or are told they do not have the condition based on an incomplete assessment. Integrative hormone practitioners, including through the Hormone Reset telehealth service, can order the full PMOS assessment panel and interpret results using functional optimal ranges rather than the broad reference ranges applied in standard pathology reports.

Conventional vs Integrative Treatment Approaches

Understanding the difference between how PMOS is typically managed in conventional care and how it is approached through a root-cause integrative lens is important for making informed decisions about your own treatment pathway.

Conventional treatments are not without value. Metformin is a well-evidenced insulin sensitiser. Letrozole has strong data for ovulation induction. The limitation of the conventional approach is not individual treatment choice but the absence of the metabolic and lifestyle foundation that determines whether any treatment produces lasting results. Metformin works better in a woman also eating to support insulin sensitivity. Ovulation induction is more likely to produce a healthy pregnancy in a woman whose inflammatory and nutritional status has been optimised first.

The Root-Cause Treatment Approach to PMOS

Effective PMOS management is a layered, personalised strategy. The sequence matters, and the foundation must be established before any targeted intervention can work to its full potential.

Step 1: Correct Insulin Resistance

Insulin resistance is the most impactful single target in PMOS. The dietary approach focuses on eliminating refined carbohydrates and processed sugars, eating adequate protein at every meal to blunt the post-meal glucose spike, including healthy fats to support hormonal synthesis without raising insulin, and eating in a way that keeps blood sugar stable across the day rather than spiking and crashing. Myo-inositol and D-chiro-inositol have the strongest evidence base of any nutritional supplement in PMOS, directly improving insulin signalling in ovarian tissue and restoring ovulation in a meaningful proportion of women with insulin-driven PMOS. Berberine is a well-evidenced insulin sensitiser with efficacy comparable to metformin in clinical trials. Resistance training is non-negotiable, as it is the most effective non-pharmacological intervention for improving insulin sensitivity in skeletal muscle.

Step 2: Reduce Androgens Through the Root

Rather than blocking androgens at the receptor level, the root-cause approach reduces androgen production by addressing the drivers. Lowering insulin reduces ovarian androgen production directly. Reducing adrenal stress reduces DHEA-S. Supporting liver androgen clearance through DIM, calcium D-glucarate, and adequate B vitamins reduces active androgen load. Saw palmetto and spearmint tea have supporting evidence for reducing free testosterone through 5-alpha reductase inhibition and androgen receptor competition respectively. These are not quick fixes. They work on the production side rather than the blocking side, which produces a different quality of outcome.

Step 3: Restore Ovulation Naturally

Ovulation is the body’s most sensitive indicator of hormonal health. In PMOS, ovulation fails because the LH surge required to trigger follicle release is disrupted by elevated insulin and androgens. As insulin and androgens normalise, ovulation typically resumes without direct ovulation induction. This process takes three to six months of consistent metabolic correction. Tracking ovulation through basal body temperature or LH strips provides objective confirmation of progress. The goal is not only a period, but a period preceded by confirmed ovulation, which indicates genuine hormonal recovery rather than breakthrough bleeding.

Step 4: Address Inflammation and Gut Health

Anti-inflammatory nutrition, including omega-3 fatty acids, turmeric, and a diverse fibre intake from non-starchy vegetables, directly reduces the inflammatory signalling that maintains androgen production and insulin resistance. Gut repair through probiotic-rich foods, prebiotic fibre, and targeted gut support where dysbiosis is identified improves insulin sensitivity, reduces systemic inflammation, and supports the oestrobolome function that governs overall hormonal balance. This layer is often the missing piece in women who have made good dietary changes without seeing the expected improvement.

Step 5: Support Mental Health Through the Hormonal Channel

PMOS-associated anxiety and depression have a direct biochemical basis: elevated androgens disrupt neurotransmitter balance, insulin resistance impairs glucose delivery to the brain, and the chronic inflammatory state reduces serotonin and dopamine availability. Addressing these hormonal drivers produces measurable mood improvement that is not achievable through psychological intervention alone when the underlying biochemistry remains dysregulated. This is covered in detail in our dedicated guide to PMOS and mental health.

Long-Term Health Implications of Unmanaged PMOS

PMOS is not solely a reproductive condition. When left unmanaged or inadequately treated, it carries meaningful long-term health risks that extend well beyond fertility. Understanding these risks is important for prioritising treatment, particularly in South Africa where access to specialist care is limited and the condition is frequently deprioritised once fertility is no longer the primary concern.

Type 2 Diabetes

Women with PMOS have a four-fold increased risk of developing type 2 diabetes compared to women without the condition. This risk is driven by the underlying insulin resistance that is central to the condition and is substantially modifiable through the lifestyle and nutritional interventions described in this guide. Insulin resistance is not a fixed state. It is a dynamic, reversible condition that responds to targeted intervention at any age.

Cardiovascular Disease

PMOS is associated with elevated cardiovascular risk through multiple mechanisms: insulin resistance drives dyslipidaemia (elevated triglycerides, low HDL), chronic inflammation damages vascular endothelium, and androgen excess contributes to unfavourable blood pressure and cardiac remodelling. These risks become clinically significant in midlife and beyond. Managing PMOS actively in the reproductive years is preventive cardiology.

Endometrial Cancer Risk

Chronic anovulation in PMOS means the endometrium is exposed to oestrogen without the opposing protective effect of progesterone, which is only produced after ovulation. Prolonged unopposed oestrogen exposure significantly increases endometrial cancer risk. Restoring ovulation, or using bioidentical progesterone to provide endometrial protection in anovulatory women, is therefore not only a fertility intervention but a cancer-risk reduction strategy.

Mental Health Burden

Women with PMOS have significantly higher rates of anxiety, depression, eating disorders, and disordered body image than the general population. These are not simply psychological reactions to having a chronic condition. They have direct biochemical drivers in the hormonal and inflammatory environment of PMOS, as explored in depth in our guide to PMOS, anxiety, and depression.